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Introduction: 
 
Definition 
 
“Lewy body dementia” (LBD) is broadly con-
sidered to consist of two related disorders- 
Parkinson’s disease dementia (PDD) and 
dementia with Lewy bodies (DLB) (Connors 
et al., 2017). Neuro-pathologically, these 
spectrum disorders are characterised by the 
widespread distribution of aggregated a-
synuclein, forming structures called Lewy 
bodies in neuronal cell bodies and processes 
(Galasko, 2017; Stubendorrf, Aarsland, 
Minthon & Londos, 2012). The abnormal 
clumping and accumulation of a-synuclein 
alters chemical processes causing a loss of 
functionality and eventually cell death (Fields, 
2017; Perkins, 2017).  
 
 
 
 
 
 
 
 
 
 
 
The diffuse distribution of pathology in LBD 
gives rise to a diverse and challenging range 
of symptoms including Parkinsonism, auto-
nomic dysfunction, recurrent hallucinations, 
cognitive fluctuations, mood disorders, REM 
sleep behaviour disorder and moderate 
memory impairment (Jellinger, 2017; Killen et 
al., 2016; McKeith et al., 2017).  
 
 PDD vs. DLB Debate 
 
Sharing of pathophysiological findings be-
tween PDD and DLB has sparked controver-
sial debate regarding whether these are two 
distinct disease processes or whether they 
are the same entity that occurs on a continu-
um (Fields, 2017). A 1-year rule was pro-
posed to split DLB and PDD; PDD is diag-
nosed if motor symptoms precede cognitive 
symptoms by more than a year; DLB is used 
if cognitive decline precedes or presents with 
the initial motor symptoms (Galasko, 2017).  
  
Some consider the separation of the two enti-
ties as being useful to enhance diagnostic 
awareness and to encourage the study of 
both phenotypes so that one day their distinct 
pathophysiology can be better understood 
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and lead to the development of disease-
modifying treatments (Friedman, 2018; 
Galasko, 2017).  
 
 Others would argue that with disease 
progression, the course of the dementia, the 
symptoms and underlying brain changes are 
more similar than different. Therefore, with 
management being the same, regardless of 
diagnosis, clinically the most appropriate and 
helpful term to encompass these two overlap-
ping syndromes is LBD.  
 
 Early Diagnosis 
 
Early identification of patients at risk of se-
vere cognitive impairment and dementia can 
help to inform choice of pharmacotherapy 
and assist with a personalised approach to 
treatment (Kehagia, Barker & Robbins, 
2010). Distinguishing LBD from other demen-
tias can be difficult particularly when shared 
Alzheimer’s (AD) pathology exists and often 
a misdiagnosis of AD is made (Galasko, 
2017; Walker, Possin, Boeve & Aarsland, 
2015).  
 
A lack of awareness of typical symptoms, 
poor familiarity with the value of obtaining a 
diagnosis and variable general practitioner 
knowledge can cause delays in obtaining an 
accurate diagnosis which contribute to overall 
feelings of burden for caregivers (Jackson et 
al., 2016; Legett, Zarit, Taylor & Galvin, 
2010). LBD is a more rapidly progressive dis-
ease than AD, early diagnosis allows caregiv-
ers and families to access interventions, plan 
for unexpected deteriorations in cognition, 
motor function and behaviour and utilise sup-
portive resources (Galvin et al., 2010). Care-
ful monitoring can assist with the prevention 
of a variety of complications and minimising 
exposure to medications that may provoke 
symptoms or cause potentially life-
threatening conditions such as severe neuro-
leptic sensitivity (Mueller, Ballard, Corbett & 
Aarsland, 2017).  
 
 
Core Clinical Features: 
 
 Fluctuating Cognition 
 
Patients with LBD are prone to spontaneous 
alterations in cognition, attention, alertness 
and arousal including staring spells, confu-
sion and incoherent speech (Galasko, 2017; 
McKeith et al., 2017). These episodes of fluc-
tuating behavioural inconsistencies discrimi-
nate LBD from other dementias and are cor-
related with increased caregiver distress 
(McKeith et al., 2017; Mueller et al., 2017). 
Planning activities in advance and scheduling 
rest periods may help to prevent tiredness 
and episodes of confusion (Londos, 2017). 
Large, randomized placebo-controlled trials 
show good evidence that the cholinesterase 
inhibitors (AchEI), Donezepil and Rivastig-
mine can improve cognition, agitation and 
attention (Stinton et al., 2015).  
 
Recurrent Hallucinations  
 
Cortical Lewy bodies in LBD are associated 
with complex recurrent visual hallucinations 
(Galasko, 2017). Vivid and well-formed false 
perceptions of people, insects or animals are 
difficult to manage because of their realistic 
details (Perkins, 2017; Walker et al., 2015). 
These phenomena are rarely reported on 
voluntarily due to variations in patient insight 
and emotional reaction and the suggestion 
that something might be wrong with them 
(Londos, 2017; McKeith et al., 2017). This 
can contribute to carer strain as a failure to 
disclose hallucinations delays treatment, af-
fects quality of life (QOL) and can ultimately 
lead to hospital admissions.  
 
The timely identification of hallucinations en-
sures access to pharmacological and psy-
chosocial interventions (Tang, Burn, Taylor & 
Robinson, 2016). With careful blood monitor-
ing for agranulocytosis, Clozapine may help 
to reduce hallucinations (Walker et al., 2015). 
Sertraline is well tolerated due to being short-
acting but must be monitored for drowsiness 
(Galasko, 2017). Input from liason neuropsy-
chologists can assist with the design and im-
plementation of treatment plans that can im-
prove the management of this disturbing and 
destructive complication (Fields, 2017).  
 
 
Parkinsonism 
 
The probable or possible diagnosis of LBD 
requires one or more spontaneous cardinal 
features of parkinsonism: Bradykinesia 
(slowness of movement and in amplitude or 
speed), rigidity or resting tremor (McKeith et 
al., 2017). The management of motor symp-
toms in LBD is complicated by a poor re-
sponse to dopaminergic treatments and an 
increased risk of psychosis (Mc Keith et al., 
2017). Levedopa is commenced slowly and 
kept to the lowest effective dose with the 
least amount of adverse reactions (Galasko, 
2017; Perkins, 2017). Dopamine agonists 
can be problematic due to their high risk of 
provoking behavioural symptoms therefore 
carers and nursing staff must maintain care-
ful vigilance. Patients at risk of falling should 
be referred to physiotherapy and occupation-
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al therapists for safety assessments. Addi-
tionally, bone density screening and assess-
ment of Vitamin D status should be done to 
minimise the risk of potentially life threatening 
fractures (McKeith et al., 2017).  
 
REM Sleep Behaviour Disorder 
 
REM Sleep Behaviour Disorder (RBD) is a 
parasomnia manifested by vivid dreams and 
complex motor movement (McKeith et al., 
2017). Dreams often have a chasing, arguing 
or attacking theme where the patient is trying 
to protect themselves. RBD is thought to 
arise due to a lack of motor inhibition during 
REM sleep (Galasko, 2017). Unfortunately 
for the carer, sleep deficit occurs for them 
also and it may be necessary to change 
sleeping arrangements to avoid injury from 
flailing limbs. RBD can be managed with the 
use of Mirtazepine and can be complement-
ed by low-dose Melatonin (Londos, 2017, 
Walker et al., 2015). In exceptional cases, 
Clonazepam may be useful with careful mon-
itoring for hypotension. Patients and carers 
must be educated about improving safety to 
minimise injury (Walker et al., 2015) and the 
potential risks of sedation, falls, cognitive 
changes and agitation with prescribed treat-
ments.  
 
Autonomic Dysfunction: 
 
Dysfunction of the autonomic system is com-
mon in LBD due to the a-synuclein pathology 
in central autonomic pathways (Galasko, 
2017). Symptoms such as excess salivation 
and sweating can be distressing and embar-
rassing and erectile dysfunction inevitably 
impacts on intimacy.  
 
Hypotension & Syncope 
 
According to Barone et al., 2009 (as cited in 
Robertson et al., 2015) light-headedness, 
fatigue, generalised weakness, headache, 
nausea and impaired cognition can impact on 
independence and decrease QOL. Postural 
blood pressure should be checked routinely 
and side effects from anti-parkinsonian medi-
cations and antidepressants should be close-
ly monitored (Stubendorff et al., 2012). Low-
dose fludrocortisone may be prescribed after 
careful consideration and review of any con-
comitant anti-hypertensives. LBD patients 
tend to have a prolonged period of orthosta-
sis after standing, therefore education about 
slow transitions from lying to sitting and 
standing position should be given. Additional-
ly, where appropriate salt and fluid intake 
should be encouraged and compression 
stockings and abdominal binders may be 
considered (Walker et al., 2015).  
 
 Urinary Incontinence 
 
Urinary incontinence contributes to sleep dis-
turbance, social isolation and carer burnout. 
Management involves regular toileting to pre-
vent anxiety and incontinence and forward 
planning for travelling. Referral to a conti-
nence nurse for continence aids and advice 
can be helpful. Oxybutynin and Solifenacin 
succinate may be prescribed to prevent ur-
gency, frequency and leakage however, the 
potential benefit must be weighed against the 
risk of worsening cognition and delirium 
(Walker et al., 2015).  
 
Constipation 
 
Constipation in LBD is thought to be linked 
with Lewy body cholinergic impairment of the 
enteric nervous system (Lepkowsky, 2017). A 
weakening of the bowel muscles, poor mus-
cle coordination and anal rectal changes 
make it difficult for bowel motions to occur 
(Vandergriendt, 2017). Encouraging a bal-
anced diet, exercise and fluids is essential for 
prevention. Patients can be guided by their 
clinicians about the best use of laxatives, 
stool softeners and probiotics.  
 
Cognitive Decline: 
 
Executive Dysfunction 
 
Deficits with working memory, set shifting 
and planning make it difficult to multi-task, 
and follow conversations and directions. Dis-
traction and the loss of train of thought during 
household sequential tasks can have implica-
tions for personal care and safety within the 
home and ultimately leads to an early loss of 
independence.  
 
Attention 
 
Fluctuations in attention and mental flexibility 
are associated with driver difficulty (Fields, 
2017). Slow reaction to sudden changes and 
a decreased ability to identify landmarks and 
traffic signs can contribute to at fault safety 
errors (Uc, Rizzo, Anderson, Spark. Rodnitz-
ky & Dawson, 2006) 
 
 Visual Spatial Disability 
 
Depth perception and judgement of distance 
are altered in LBD. Severe difficulties with 
visuospatial functioning can predict rapid de-
cline and the development of hallucinations 
(Walker et al., 2015). Clumsiness, trips, falls, 
mishaps around the home and misjudging 
distances are sensitive issues to report but 
need to be explored to inform treatment 
choices and ensure patient safety.  
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Mood and Personality Changes: 
 
             Anxiety 
 
Fluctuating cognitive and motor function in 
LBD can contribute to worry, phobias and 
panic attacks. Heightened levels of anxiety 
can worsen parkinsonism leading to the 
avoidance of activities, social and emotional 
isolation and poor QOL (Fields, 2017). New 
situations and surroundings can cause confu-
sion and panic which places limits on social-
ising and holidaying. These unpredictable 
mood changes can be a major stressor for 
carers and family members. The provision of 
education and early referrals for respite sup-
port can help to alleviate carer burden.  
 
Benzodiazepines, such as Diazepam and 
Lorazepam can be prescribed cautiously for 
their calming effect with careful monitoring for 
sedation, confusion and paradoxical agita-
tion.  
 
           Apathy 
 
Reduced initiative and motivation combined 
with overwhelming fatigue and hypersomnia 
can be some of the most disabling features of 
LBD. Seretonin norepinephrine reuptake in-
hibitor (SSRI) anti-depressants may be worth 
a try and can be combined with Modafanil as 
a stimulant (Bomasang –Layno, Fadland, 
Murray & Himelhoch, 2015).  
 
          Depression 
 
The unpredictability of LBD makes it a very 
isolating condition with patients often feeling 
like they are trapped in their own bodies. Dur-
ing times when insight and clarity are re-
tained, patients can become frustrated with 
the increasing perception of burden. Impul-
sivity, disinhibition and emotional lability can 
contribute to awkward interactions and con-
tributes to high dependency on spouses and 
carers and restrictions in social and living 
arrangements (Mueller et al., 2017). Ven-
lafaxine and Melatonin can be used to im-
prove sleep and reduce depressive symp-
toms  
 
(Londos, 2017). SSRIs such as Sertraline 
and Citalopram are most commonly used due 
to safer tolerability (Perkins, 2017) however, 
Fluoxetine and Paroxetine may also have a 
role in managing anxiety and depression with 
careful monitoring for gastrointestinal side 
effects.  
 
 
 
 
 
Neuropsychiatric Complications: 
          
llusions  
 
Objects, shadows and patterns can often be 
misinterpreted as people or animals 
(Galasko, 2017) and these misperceptions 
can have implications for mood and safety 
depending on a patient’s reaction to these 
distorted visual stimuli.  
 
      Delusions 
 
There is often a paranoid theme to delusions 
in LBD with a focus on spousal infidelity, theft 
and home intruders (Goldman et al., 2014; 
Perkins, 2017). Capgras Syndrome is the 
most common unusual delusional syndrome 
where the spouse or close relative of a pa-
tient is believed to have been replaced by an 
imposter (Perkins, 2017; Moro et al., 2013). 
Reduplicative Paramnesia occurs when it is 
believed that a place simultaneously exists in 
2 or more physical locations (Devinsky, 
2009). 
 
    The reoccurrence of these symptoms con-
tributes to carer burden which ultimately 
leads to more frequent hospital admissions, 
longer length of stay and accelerated nursing 
home placement compared to AD (Mueller et 
al., 2018). Clinicians need to be aware of 
these rare conditions so that factors such as 
pain, infection and interpersonal and environ-
mental triggers that impact on delusions and 
agitation can be treated appropriately 
(Galasko, 2017; Moro et al., 2013).  Carers 
should be encouraged to utilise family and 
community supports for regular scheduled 
respite to prevent carer burnout. A reduction 
of higher doses of levodopa may lead to an 
improvement in symptoms  
 
(Galasko, 2017; Moro et al., 2013). Case re-
ports have shown that Gabapentin can re-
duce the symptoms of agitation (Stinton, et 
al, 2015). Pimavanserin recently received 
FDA approval for hallucinations and delu-
sions associated with PD psychosis 
(Cummings, Isaacson , Mills, Williams, Chi-
Burris, Corbet, Dhall & Ballard, 2014).   
 
Care Planning: 
 
In LBD cognitive decline, greater 
caregiver burden and a greater effect on 
quality of life seems to be more accelerated 
than in AD.  These circumstances need to be 
considered when contemplating long-term 
treatment (Mueller et al., 2017). The extent of 
the burden on people with LBD and their car-
ers calls for the development of comprehen-
sive and individualised care plans including 
pharmacological and non-pharmacological 
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interventions (Morrin et al., 2018). As the dis-
ease progresses, this complex, multi-system 
disease requires multiple providers and on-
going communication and collaboration.  
 
Nurses as often the first point of con-
tact, are in a unique position to assess the 
need for caregiver support and education and 
to refer to social networks, community organi-
sations and aged care and disability assess-
ment teams for personal care, respite and 
permanent care approvals. 
 
Early referral to allied health professionals for 
safety concerns can assist with keeping pa-
tients in the home for as long as possible. 
Social workers can assist with understanding 
government carer entitlements and the legali-
ties of Patient Consent, Living Wills, Power of 
Attorney and Guardianship. Furthermore, 
nurses can help carers and families prepare 
for emergencies by providing education 
about the disease and medication complica-
tions and empowering them to be able to ad-
vocate for the patient in acute care settings 
where LBD may be poorly understood.  
 
To alleviate any pressure on family members 
to make difficult decisions during a crisis, ear-
ly discussions about Advanced Care Direc-
tives and long-term care preferences should 
be conducted and documented while the pa-
tient has insight and can have input into their 
future care.  
 
 Since patients may not always be 
forthcoming about their level of functioning 
and carers may be reluctant to speak out of 
turn, clinicians need to be astute in their as-
sessment of their patient’s situation. Ques-
tions regarding personal care, managing 
medication and finances, driving, falls, safety 
in the home, exercise, cognitive stimulation 
and social interaction should be included in 
consultation to gain further insights into the 
day-day issues.  
  
Conclusion: 
 
 In the absence of any cure or protec-
tive therapies for LBD, we need to take a wid-
er approach to research and the provision of 
specialty health services. 
 
 The poor prognosis and high burden 
of care call for new treatment studies for LBD 
to be prioritised (Mueller et al., 2017). A bet-
ter understanding of the pathophysiologic 
mechanisms and prodromal states of these 
diseases may lead to more accurate diagno-
sis and the development of disease modify-
ing and symptomatic treatments. Eligibility 
criteria need to be considered so that trials 
can be designed specifically to investigate 
LBD and expand the evidence base (Morrin 
et al., 2018). The development of compre-
hensive clinical guidelines for the manage-
ment of LBD will require robust interventional 
trials evaluating the efficacy of combined 
pharmacological and non-pharmacological 
interventions to inform best practice (Morrin 
et al., 2018).  
 
By raising awareness in the general commu-
nity and developing more support resources 
specific to LBD, this may help to generate 
interest and understanding and reduce the 
stigma associated with this more rapidly pro-
gressive but lesser known form of dementia 
(Legett et al., 2010). Additionally, addressing 
the gap in knowledge of clinicians, patients 
and caregivers should be prioritised to en-
sure patients receive timely and appropriate 
treatments and support to be able to face the 
unique challenges of navigating these largely 
unchartered waters.  
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Vale: Sr. Elizabeth Naigaga 
 
Last month the Neuroscience Nursing community lost  a great and 
inspiring nurse. Elizabeth Naigaga was the head nurse of the first 
ICU at Mulago National Referral Hospital in Kampala, Uganda.  
Through her tenacity and perseverance she strived to improve both 
care and facilities  in Uganda, including the development of a  neu-
rosurgical high dependency unit. It was through her mentoring and 
leadership that she continued to improve care and services at the 
Mulago ICU  
In 2013, some of us were lucky enough to meet and hear Elizabeth 
present at the11th Quadrennial WFNN Congress in Gifu, Japan. 
Elizabeth lost her battle with cancer in May. This, the loss of a truly 
incredible, dedicated and passionate neuroscience nurse. 
Elizabeth's passion to change the world she lived in will be hon-
oured by a creating a scholarship fund in her name to benefit an 
African nurse with limited resources to attend an international nurs-
ing conference with WFNN, NCS or AANN.  (Original story  https://
wfnn.org/) 
